SWOG clinical trial number
S0702

"A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients with Bone Metastases Starting Zoledronic Acid Treatment"

Closed
Phase
Accrual
100%
Published
Abbreviated Title
CANCER CONTROL: Prospective ONJ Trial
Status Notes
Status Notes: NOTE: The url for ordering specimen kits for this study has changed. Please use the following link: https://ricapps.nationwidechildrens.org/KitManagement
Activated
12/15/2008
Closed
12/13/2013
Participants
NCORP, Members, CTSU, Affiliates

Research committees

Symptom Control and Quality of Life
Breast Cancer
Genitourinary Cancer
Lung Cancer
Myeloma

Eligibility Criteria Expand/Collapse

Bone metastasis from multiple myeloma, solid tumor, other malignancy where bisphosphonate is indicated; planned treatment with zoledronic acid;</= 3 doses IV ibandronate, pamidronate or zoledronic acid in past 3 years for osteopenia or osteoporosis; </= 90 days IV ibandronate, pamidronate, or zoledronic acid for metastatic bone disease; sum of IV bisphosphonate doses must not be > 4. Zubrod PS 0-3; willing to provide information regarding smoking history, alcohol consumption, pain assessments; willing to undergo dental assessments per protocol; willing to provide access to prior and future dental information; participation in other therapeutic or non-therapeutic trials is o.k.

0.5 Cancer Control Credits for initial registration (see funding memo for additional information about credits).

Publication Information Expand/Collapse

2023

Early Mortality Risk with Non-Intensive Acute Myeloid Leukemia (AML) Therapies: Analysis of 1,336 Patients from MRC/NCRI and SWOG

M Othus;I Thomas;X Wang;C Ariti;P Mehta;M Sydenham;R Hills;A Burnett;S Nand;S Assouline;L Michaelis;H Erba;N Russell;K Kerr;R Walter;M Dennis Leukemia and Lymphoma Jan;64(1):250-252

PMid: PMID36226777

2021

Association of Osteonecrosis of the Jaw With Zoledronic Acid Treatment for Bone Metastases in Patients With Cancer

C Van Poznak;J Unger;A Darke;C Moinpour;R Bagramian;M Schubert;L Hansen;J Floyd;S Dakhil;D Lew;J Wade;M Fisch;NL Henry;D Hershman;J Gralow JAMA Oncology 2021 Feb 1;7(2):246-254. doi: 10.1001/jamaoncol.2020.6353; Dec 17;e206353. doi: 10.1001/jamaoncol.2020.6353. Online ahead of print

PMid: PMID33331905 | PMC number: PMC7747039

2019

Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases: SWOG S0702, NCT00874211

C Van Poznak;J Unger;A Darke;C Moinpour;R Bagramian;L Hansen;J Floyd;S Dakhil;D Lew;J Wade;M Fisch;NL Henry;D Hershman;J Gralow J Clin Oncol 37 (suppl; abstr 11502);ASCO Annual Meeting (May 31-June 4, 2019, Chicago, IL), oral

2017

Dental health status and patient-reported outcomes at baseline in patients participating in the osteonecrosis of the jaw registry study, SWOG S0702

C Van Poznak;A Darke;C Moinpour;RA Bagramian;MM Schubert;J Gralow;J Wade;J Unger Supportive Care in Cancer 2017 Apr;25(4):1191-1199; Dec 7 [Epub ahead of print]

PMid: PMID27928641 | PMC number: PMC5323355

Other Clinical Trials

SWOG Clinical Trial Number
CTSU/NRG-BR007

A Phase III Clinical Trial Evaluating De-escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score </= 18 Breast Cancer
Research Committee(s)
Breast Cancer
Activated
06/07/2021
Open
Phase
SWOG Clinical Trial Number
CTSU/A011801

The COMPASSHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in Her2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib
Research Committee(s)
Breast Cancer
Symptom Control and Quality of Life
Activated
01/06/2021
Open
Phase
SWOG Clinical Trial Number
S2007

A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients with HER2-Negative Breast Cancer and Brain Metastases
Research Committee(s)
Breast Cancer
Activated
12/15/2020
Accrual
43%
Open
Phase